Baseline Suvmax Correlates with Tumor Hypoxia and Patient Outcomes in Nasopharyngeal Carcinoma: Employing Transcriptomic Gene Signature Analysis

Author:

Ding Jianming1,Li Qian1,Lin Yuhao1,Zheng Xiaobing1,Huang Chaoxiong1,Hong Jiabiao1,Fei Zhaodong1,Chen Chuanben1

Affiliation:

1. Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital

Abstract

Abstract

Objective: To assess the prognostic relevance of the maximum standard uptake value (Suvmax) in Nasopharyngeal carcinoma (NPC), establish a gene signature correlated with Suvmax and explore the potential biological mechanisms underlying these associations for predicting clinical outcomes. Methods: A cohort of 726 NPC patients underwent analysis to determine correlations between Suvmax and various clinical variables, including tumor stage, metabolic tumor volume (MTV), and lactate dehydrogenase (LDH) levels. RNA sequencing data was utilized to identify genes related to Suvmax, which were then used to develop a 'Suv-signature'. Additionally, transcriptome enrichment analysis was conducted to investigate the potential biological mechanisms underlying the observed correlations. Results:Higher Suvmax values were associated with increased tumor burden and worse prognosis. The 'Suv-signature' consisting of 10 genes, showed a positive correlation with Suvmax and predicted poorer survival outcomes. This signature was highly expressed in malignant epithelial cells and was associated with hypoxia and resistance to radiotherapy. Additionally, the signature showed a negative correlation with immune function. Conclusion: Suvmax is a valuable prognostic indicator in NPC, with higher values predicting worse outcomes. The 'Suv-signature' offers further prognostic insights, linking glucose metabolism to tumor aggressiveness, treatment resistance, and immune function, and may serve as a potential biomarker for NPC.

Publisher

Springer Science and Business Media LLC

Reference35 articles.

1. Nasopharyngeal carcinoma;Chen YP;Lancet,2019

2. Nasopharyngeal carcinoma: an evolving paradigm;Wong KCW;Nat Rev Clin Oncol,2021

3. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial [published correction appears in Lancet. 2016;388(10054):1882]. Lancet. 2016;388(10054):1883–1892.

4. Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer;Sanli Y;Clin Nucl Med,2018

5. Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma;Xia H;Eur J Nucl Med Mol Imaging,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3